Search tips
Search criteria 


Logo of apmJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
Adv Prev Med. 2012; 2012: 731604.
Published online 2011 October 17. doi:  10.1155/2012/731604
PMCID: PMC3199075

Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges


The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism agents is an important component of the US biodefense program. DVC is developing two vaccines, one against inhalational exposure to botulinum neurotoxins A1 and B1 and a second for Yersinia pestis, with the ultimate goal of licensure by the FDA under the Animal Rule. Progress has been made in all technical areas, including manufacturing, nonclinical, and clinical development and testing of the vaccines, and in assay development. The current status of development of these vaccines, and remaining challenges are described in this chapter.

Articles from Advances in Preventive Medicine are provided here courtesy of Hindawi Publishing Corporation